Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.
Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin
DRUG: PCI-24781
Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response, Number of patients experienced DLT in each cohort, From the Date of PCI-24781 first administration to Cycle 2 Day 1|Phase II: Overall Response Rate (CR+PR), From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles
The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 2 different types of lymphoma patients.